|
|
Vol. 14.17 – 12 May, 2023
|
|
|
|
|
|
|
|
Researchers sought in vivo genetic evidence for, and mechanistic understanding of, the role of B7 homolog 3 protein (B7-H3) in PTEN/TP53-deficient prostate cancer. [Science Translational Medicine]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Scientists demonstrated that atypical ubiquitination of androgen receptor mediated by an E3 ubiquitin ligase TRAF4 played an important role in castration-resistant prostate cancer development.
[Proceedings Of The National Academy Of Sciences Of The United States Of America]
|
|
|
|
|
|
The authors explored the mechanisms and potential combinatorial approaches with Cyst(e)inase for treatment of prostate cancer.
[Journal of Experimental & Clinical Cancer Research]
|
|
|
|
|
|
Investigators reported that NR3C1, the gene encoding glucocorticoid receptor, was a novel sex determining region Y-box 2 (SOX2) target in prostate cancer, positively regulating its expression.
[Cancer Letters]
|
|
|
|
|
|
The authors reported that silencing of transglutaminase-2 expression by CRISPR-Cas9 was associated with upregulation of androgen receptor transcription in prostate cancer cell lines.
[Cell Death & Disease]
|
|
|
|
|
|
Researchers showed that although Wnt was essential for prostate epithelial basal stem cell multipotency, ectopic Wnt activity promoted basal cell over-proliferation and squamous phenotypes, which were counteracted by elevated levels of androgen.
[Stem Cell Reports]
|
|
|
|
|
|
Investigators examined the expression of B7-H3 in prostate cancer tissues and cells and developed a second-generation chimeric antigen receptor (CAR) that specifically targeted B7-H3 and CD28 as costimulatory receptor to explore its tumoricidal potential against prostate cancer in vitro and in vivo.
[Cell Death Discovery]
|
|
|
|
|
|
Scientists investigated underlying mechanism of jumonji domain 2A (JMJD2A) in regulating cytoskeleton remodeling in castration-resistant prostate cancer resistant to docetaxel.
[BMC Cancer]
|
|
|
|
|
|
Researchers explored whether the FFA C8:0 could promote the progression of prostate cancer by up-regulating Krüppel-like factor 7. [BMC Cancer]
|
|
|
|
|
|
|
|
Scientists review a comprehensive catalogue of single-cell omics studies and provide a more thorough understanding of the diagnosis and treatment of prostate cancer.
[Cellular & Molecular Biology Letters]
|
|
|
|
|
|
Investigators discuss new roles for androgen receptors (ARs) in other cancer types as well as their potential for treatment with AR-targeted agents. [Endocrinology]
|
|
|
|
|
|
|
|
INmune Bio, Inc. announced that the US FDA has cleared the Investigational New Drug (IND) application for INKmuneâ„¢, a novel natural killer cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic castration-resistant prostate cancer. [INmune Bio, Inc.]
|
|
|
|
|
|
|
|
June 2 – 6, 2023 Chicago, Illinois, United States
|
|
|
|
|
|
|
|
|
|
|
Pfizer – New York, New York, United States
|
|
|
|
|
|
|
The Brady Urological Institute – Baltimore, Maryland, United States
|
|
|
|
|
|
|
Case Western Reserve University – Cleveland, Ohio, United States
|
|
|
|
|
|
|
Harvard T.H. Chan School of Public Health – Boston, Massachusetts, United States
|
|
|
|
|
|
|
University of Miami Desai Sethi Urology Institute – Miami, Florida, United States
|
|
|
|
|
|